

FORM PTO-1390U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV. 5-93)		ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		3477.92
		U.S. APPLICATION NO. (If known see 37 C.F.R. 1.5)
		09/856324
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/CA99/01106	19 November 1999	19 November 1998
TITLE OF INVENTION		
COMPOSITION AND USE OF RAR ANTAGONISTS FOR PROMOTING CHONDROGENESIS		
APPLICANT(S) FOR DO/EO/US		
UNDERHILL, Tully Michael; WESTON, Andrea Dawn		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1.	<input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.	
2.	<input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.	
3.	<input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).	
4.	<input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.	
5.	<input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))	
6.	a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).	
7.	b. <input type="checkbox"/> has been transmitted by the International Bureau.	
8.	c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).	
9.	<input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).	
10.	<input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))	
11.	a. <input checked="" type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).	
12.	b. <input type="checkbox"/> have been transmitted by the International Bureau.	
13.	c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.	
14.	d. <input type="checkbox"/> have not been made and will not be made.	
15.	<input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).	
16.	<input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).	
17.	<input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).	
Items 11. to 16. below concern other document(s) or information included:		
11.	<input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.	
12.	<input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.	
13.	<input type="checkbox"/> A FIRST preliminary amendment.	
14.	<input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.	
15.	<input type="checkbox"/> A substitute specification.	
16.	<input type="checkbox"/> A change of power of attorney and/or address letter.	
17.	<input checked="" type="checkbox"/> Other items or information: Copy of International Preliminary Examination Report	

JC18 Rec'd PCT/PTO 1 8 MAY 2001

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.50) <b>097856324</b>		INTERNATIONAL APPLICATION NO. PCT/CA99/01106		ATTORNEY'S DOCKET NUMBER 3477.92	
---	--	---	--	-------------------------------------	--

17. <input checked="" type="checkbox"/> The following fees are submitted: <b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b> Search Report has been prepared by the EPO or JPO .....\$860.00  International preliminary examination fee paid to USPTO (37 CFR 1.482).....\$690.00  No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .....\$710.00  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$1000.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT = \$1,000.00 Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)). \$ <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:15%;">Claims</th> <th style="width:15%;">Number Filed</th> <th style="width:15%;">Number Extra</th> <th style="width:15%;">Rate</th> <th style="width:15%;"></th> <th style="width:15%;"></th> </tr> <tr> <td>Total Claims</td> <td>29-20 =</td> <td>9</td> <td>X \$18.00</td> <td>\$162.00</td> <td></td> </tr> <tr> <td>Independent Claims</td> <td>13-3 =</td> <td>10</td> <td>X \$80.00</td> <td>\$800.00</td> <td></td> </tr> <tr> <td colspan="3">Multiple dependent claim(s) (if applicable)</td> <td>+ \$270.00</td> <td>\$</td> <td></td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$1,962.00</td> <td></td> </tr> </table> Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28). \$ SUBTOTAL = \$1,962.00 Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). \$ TOTAL NATIONAL FEE = \$1,962.00 Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + TOTAL FEES ENCLOSED = \$1,962.00 <div style="text-align: right; margin-top: 10px;">             Amount to be refunded \$              charged \$           </div>				Claims	Number Filed	Number Extra	Rate			Total Claims	29-20 =	9	X \$18.00	\$162.00		Independent Claims	13-3 =	10	X \$80.00	\$800.00		Multiple dependent claim(s) (if applicable)			+ \$270.00	\$		TOTAL OF ABOVE CALCULATIONS =				\$1,962.00			
Claims	Number Filed	Number Extra	Rate																																
Total Claims	29-20 =	9	X \$18.00	\$162.00																															
Independent Claims	13-3 =	10	X \$80.00	\$800.00																															
Multiple dependent claim(s) (if applicable)			+ \$270.00	\$																															
TOTAL OF ABOVE CALCULATIONS =				\$1,962.00																															

☒ A check in the amount of \$1,962.00 to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$\_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0220.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

ALL CORRESPONDENCE TO:

eth D. Sibley

s Bigel Sibley & Sajovec

Office Box 37428

gh, North Carolina 27627

"Express Mail" mailing label number EL733094469US  
Date of Deposit May 18, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Commissioner for Patents, Washington, D.C. 20231.

*Vickie Diane Prior*  
Vickie Diane Prior  
Date: May 18, 2001

*Mr. Sibley*  
SIGNATURE

No. 31,665  
REGISTRATION NUMBER

#3

PATENT

6

Group Art Unit: Unknown  
Examiner: Unknown


BOX PCT  
Commissioner for Patents  
Washington, DC 20231

Sir:

### --Related Applications

REMARKS

Respectfully submitted,

  
Kenneth D. Sibley  
Registration No. 31.665

**USPTO Customer No. 20792**  
Myers Bigel Sibley & Sajovec  
Post Office Box 37428  
Raleigh, North Carolina 27627  
Telephone (919) 854-1400  
Facsimile (919) 854-1401

In re: Underhill, et al.  
Serial No. : 09/856,324  
Filed: 18 May 2001  
Page 2

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX PCT, Commissioner for Patents, Washington, DC 20231, on June 28, 2001.



Vickie Diane Prior

Date of Signature: June 28, 2001

COMPOSITION AND USE OF RAR ANTAGONISTS FOR PROMOTING CHONDROGENESIS**Field of the Invention**

5           The invention relates to compositions for promoting chondrogenesis and to methods for treating cartilage and bone abnormalities resulting from injury or disease and for *ex vivo* tissue engineering.

**Background of the Invention**

10           Retinoic acid (RA) is known to have an important signalling role in the regulation of embryonic development and cell differentiation. The biological effects of RA are transduced via two classes of nuclear receptors, designated retinoic acid receptors (RAR $\alpha$ , RAR $\beta$  and RAR $\gamma$ ) and retinoid X receptors (RXR $\alpha$ , RXR $\beta$  and RXR $\gamma$ ) (Giguere et al., (1987), Nature, 350, 624-629).

15           Many studies have been made of the role of RA and its receptors in the process of chondrogenesis and skeletal development. For example, down regulation of RAR $\alpha$  has been stated to be important for chondrogenic expression (Cash et al, 1997). Down regulation of RAR- $\beta$ 2 using antisense oligonucleotides was found to stimulate chondrogenesis and thus it was suggested that RAR- $\beta$ 2 helps to prevent  
20           mesenchymal cells from expressing their chondrogenic bias (Jiang et al., 1995). Underhill et al 1998 reported that abnormal expression of RARs inhibits chondrogenesis. However, it was also found that absence of RAR can lead to deficiencies in cartilage formation while also promoting chondrogenesis at ectopic sites.

25           Addition of RA and RAR-specific agonists has been shown to inhibit cartilage formation in limb bud micromass cultures, and act as a teratogen *in vivo* to negatively affect skeletal development (Kistler, 1987; Kochhar, 1973; Kochhar and Aydelotte, 1974; Kwasigroch and Kochhar, 1980). In contrast, addition of retinoic acid to micromass cultures has also been demonstrated to stimulate cartilage formation (Ide  
30           and Aono, 1988; Paulsen et al., 1994a; Paulsen et al., 1994b).

Addition of an RAR antagonist completely reversed the inhibitory action of an RAR agonist on chondrocyte differentiation in rat and mouse embryo limb bud mesenchymal cells *in vitro* (Eckhardt et al., (1994), Toxicol. Letters, 70, 299-308; Kocchar et al., (1998), Int. J. Dev. Biol., 42, 601-608). These authors, however, found that the antagonist alone had no effect on limb bud mesenchymal cell differentiation.

The precise role of RARs in chondrogenesis was unclear from these studies. Specifically, it was unclear whether RARs functioned to inhibit chondrogenesis or stimulate that process. Overall, the role of RAR antagonists in the process of chondrogenesis was not clearly established.

#### **Summary of the Invention**

It has now been demonstrated that RAR activity alone has a fundamental role in controlling the transition of chondroprogenitor cells into chondrocytes. It has also now been demonstrated that administration of RAR antagonists can initiate chondrogenesis and stimulate cartilage formation *in vitro* and *in vivo*. Furthermore, it is now also demonstrated that administration of a RAR antagonist can rescue cartilage formation. This provides a basis for the development of therapeutic compositions and uses of such compositions to treat disorders involving abnormal cartilage formation.

The present invention now provides therapeutic compositions and methods for the treatment of disorders involving abnormal cartilage formation and associated abnormal skeletal development resulting from disease or due to trauma.

In accordance with one embodiment, the present invention provides a pharmaceutical composition comprising an effective amount of an RAR antagonist and, optionally, a pharmaceutically acceptable carrier.

RAR antagonists for use in the present invention are characterized by having a stimulating effect on cartilage formation and as a result on associated bone development in a vertebrate. RAR antagonists may be defined as any chemical that binds to one or more of the RAR subtypes with a Kd of less than 1 micromolar. Conventionally, a RAR antagonist is a chemical agent that inhibits the activity of an RAR agonist.

In accordance with a further embodiment, the invention provides a method for stimulating cartilage formation in a vertebrate, the method comprising administering to the vertebrate an effective cartilage formation stimulating amount of an RAR antagonist.

5 In accordance with a further embodiment, the invention provides a method for treating damaged cartilage and associated bone in a subject, comprising administering to the subject an effective amount of an RAR antagonist, wherein the RAR antagonist stimulates cartilage repair and formation which mediates associated bone repair.

10 In accordance with a further embodiment, the invention provides a method for enhancing osseous integration of orthopedic or dental implants in a subject comprising administering to the subject an effective amount of an RAR antagonist.

In accordance with a further embodiment, the invention provides a method for treating arthritis in a subject, comprising administering to the subject an effective amount of an RAR antagonist.

15 In accordance with a further embodiment, the invention provides a method for treating arthritis in a subject, comprising administering to the subject chondrogenic cells treated with an effective amount of an RAR antagonist.

20 According to one embodiment of the invention, there is provided a composition for inducing chondrogenesis and associated skeletal development in a vertebrate, the composition comprising:

- a RAR antagonist; and
- a pharmaceutically acceptable carrier.

25 According to another embodiment of the invention, there is provided a morphogenic device for implantation at a cartilage site in a vertebrate, the device comprising:

- an implantable biocompatible carrier; and
- a RAR antagonist dispersed within or on said carrier.

30 According to yet another embodiment of the invention, there is provided the use of a composition comprising a RAR antagonist and a pharmaceutically acceptable carrier, for inducing chondrogenesis *in vitro*.

According to yet another embodiment of the invention, there is provided a method for producing a chondrocyte from a chondroprogenitor mesenchymal cell

comprising contacting a chondroprogenitor mesenchymal cell with a RAR antagonist *in vitro*.

According to another embodiment of the invention, there is provided an implantable prosthetic device for repairing cartilage-associated orthopedic defects, injuries or anomalies in a vertebrae, the device comprising:

- a prosthetic implant having a surface region implantable adjacent to or within a cartilage tissue.
- a RAR antagonist composition disposed on the surface region in an amount sufficient to promote enhanced cartilage growth into the surface.

According to another embodiment of the invention, there is provided a method for promoting *in vivo* integration of an implantable prosthetic device into a target cartilage tissue of a vertebrae, the method comprising the steps of:

- providing on a surface of the prosthetic device a composition comprising a RAR antagonist and a pharmaceutically acceptable carrier and
- implanting the device in a vertebrae at a site where the target cartilage tissue and the surface of the prosthetic device are maintained at least partially in contact for a time sufficient to permit tissue growth between the target cartilage tissue and the device.

According to yet another embodiment of the invention, there is provided a method for promoting natural bone formation at a site of skeletal surgery in a vertebrae, the method comprising the steps of delivering a RAR antagonist composition to the site of the skeletal surgery whereby such delivery indirectly promotes the formation of new bone tissue mediated by cartilage.

According to another embodiment of the invention, there is provided a method for repairing large segmental skeletal gaps and non-union fractures arising from trauma or surgery in a vertebrae, the method comprising delivering a RAR antagonist composition to the site of the segmental skeletal gap or non-union fracture whereby such delivery promotes the formation of cartilage which mediates new bone tissue formation.

According to yet another embodiment of the invention, there is provided a method for aiding the attachment of an implantable prosthesis to a cartilage site and for maintaining the long term stability of the prosthesis in a vertebrae, the method



comprising coating selected regions of an implantable prosthesis with a RAR antagonist composition and implanting the coated prosthesis into the cartilage site, whereby such implantation promotes the formation of new cartilage tissue and indirectly stimulates bone formation.

5 According to a further embodiment of the invention, there is provided a method of producing cartilage at a cartilage defect site *in vivo*, the method comprising:

- implanting into the defect site a population of chondrogenic cells which have been cultured *in vitro* in the presence of a RAR antagonist.

10 According to another embodiment of the invention, there is provided a method for treating a degenerative joint disease characterized by cartilage degeneration, the method comprising:

- delivering a therapeutically effective amount of a RAR antagonist to a disease site.

15

#### **Summary of the Drawings**

The present invention will be further understood from the following description with reference to the Figures, in which:

20 Figure 1 shows photomicrographs of transgene-expressing cells. Panels (A-C) show wild-type fore limb cultures stained with alcian blue on days 2, 4 and 6. Panels (D-G) show transgenic fore limb cultures stained with magental-gal followed by alcian blue at days 2, 4 and 6. Panel (D) shows higher magnification of day 4 transgenic fore limb cultures. Transgene-expressing cells are excluded from the cartilage nodules. Panel (H) shows day 4 transgenic hind limb cultures. Transgene-expressing cells are much more abundant compared to fore limb cultures, and hence only a few small cartilage nodules have formed. Bar: (A-C, E-H) 1.0 mm (D) 0.4 mm.

30 Figure 2A shows photomicrographs of transgene-expressing cells. Panels (A-H) show whole mount *in situ* hybridization of wild-type and transgenic cultures carried out using probes characteristic of specific stages of chondrogenesis. Panel (A)

shows Col II expression is very abundant in wild-type cultures. Panel (B) shows Col II expression in transgenic cultures is much weaker and has a more widespread distribution. Panels (C, E, G) show wild-type cultures, N-cad, gli-1, and col I are all abundantly expressed in perinodular regions but are only weakly expressed in the core of the nodules. Panels (D, F, H) show that in transgenic cultures, N-cad, gli-1 and col-I are expressed throughout the cultures with no apparent downregulation as seen in the center of the nodules of wild-type cultures. Bar: (A-H) 0.4 mm.

Figure 2B shows the results of northern blot analysis using total hind limb bud RNA indicating that col II is downregulated in transgenic hind limbs at E 14.5, and gli-1 is downregulated in transgenic hind limbs at E 12.5.

Figure 3 shows transgene-expressing cells respond differently to BMP-2. Panel (A) shows quantitative analysis of nodule formation *in vitro*. There are fewer cartilage nodules in the fore and hind limb cultures of untreated transgenic cultures compared to those in untreated wild-type cultures. BMP-2 treatment increases the number of nodules in both wild-type and transgenic cultures, however, the increase seen in wild-type cultures is more dramatic. Panels (B-D) show wild-type cultures treated with BMP-2 stained with alcian blue at days 2, 4 and 6. In response to BMP-2, there is a noticeable increase in nodule number and in nodule size, with cartilage nodules located at the periphery of the cultures becoming the largest. Panels (F-H) show transgenic cultures treated with BMP-2 and stained with magenta-gal followed by alcian blue at days 2, 4 and 6. In response to BMP-2 there is an increase in nodule number and in nodule size. There are also many more condensations of transgene-expressing cells. Panel (E) shows higher magnification of day 4 wild-type cultures treated with BMP-2. Panel (I) shows higher magnification of day 4 transgenic cultures treated with BMP-2. BMP-2 stimulates condensation of transgene-expressing cells, but they remain excluded from cartilage nodules. Bar: (A-C, E-G) 1.0 mm (D, H) 0.4 mm.

Figure 4 shows Col II expression is altered in transgenic cultures. Panels (A, B) show Col II expression in wild-type and transgenic cultures respectively. In wild-

type cultures, col II is abundantly expressed within cartilage nodules and is much weaker in transgenic cultures with a less distinct expression pattern. Panel (C) shows that in response to BMP-2 the number of cartilage nodules in wild-type cultures that express col II abundantly increases. Panel (D) shows that in transgenic cultures treated with BMP-2 there are a few nodules with abundant col II expression and several condensations with weaker expression. Bar: (A-D) 0.4 mm.

Figure 5 shows BMP-2 and AGN194301 exhibit different chondrogenic stimulatory properties. Panel (A) shows untreated wild-type cultures stained with alcian blue on day 6. Panels (B, C) show wild-type cultures treated with BMP-2 for the first two days and three days of culture, respectively, and stained with alcian blue on day 6. These cultures resemble untreated cultures. Panel (D) shows wild-type cultures treated continuously with BMP-2 and stained with alcian blue on day 6. Panels (E, F) show wild-type cultures were treated after two or three days respectively and stained with alcian blue on day 6. These cultures resemble cultures that were treated continuously with BMP-2. Panel (G) shows untreated wild-type cultures stained with alcian blue on day 8. Panels (H, I) show wild-type cultures treated with AGN194301 for the first two days and three days of culture, respectively, and stained with alcian blue on day 8. These cultures resemble cultures treated continuously with AGN194301 in that there are several more smaller nodules. Panel (J) shows wild-type cultures were treated continuously with AGN194301 and stained with alcian blue on day 8. Panels (K, L) show wild-type cultures treated after two or three days respectively and stained with alcian blue at day 8. The size and number of cartilage nodules is less compared to cultures treated continuously. Bar: (A-L) 1.0 mm. Panel (M) shows quantification of cartilage nodule formation in response to BMP-2 and AGN194301. In response to BMP-2, or AGN194301 alone, there is a dramatic increase in the number of nodules that form. When BMP-2 and AGN194301 are added together, the number of nodules formed is greater than when each is added alone.

Figure 6 shows the rescue of cartilage formation in Noggin-treated cultures by addition of AGN194301. Panel (a) shows wild-type cultures stained with alcian blue

on day 6. Panel (b) shows wild-type cultures treated with Noggin (10ng/ml) and stained with alcian blue on day 6. In comparison to control cultures, only a few weakly stained nodules are evident and these are present within the center of the culture where cell density is highest. Panel (c) shows wild-type cultures treated with 10ng/ml Noggin and 1  $\mu$ M AGN194301. When Noggin and AGN 194301 are added together, there is no apparent decrease in nodule formation in comparison to untreated cultures. Similar to that observed in control cultures, nodules are distributed throughout the culture. Panel (d) shows the quantification of cartilage nodule formation in response to Noggin and AGN194301. Treatment of Noggin alone dramatically reduced the number of cartilage nodules to ~10% of that of control cultures. Addition of AGN194301 to Noggin-treated cultures rescues cartilage formation and leads to an increase in cartilage nodule formation comparable to that of control cultures. Panels (e, f) show the analysis of col IIa and col II expression in Noggin-treated cultures, respectively, revealing a comparable number of col 2a expressing aggregates and col II expressing nodules. The bar represents 1 mm.

### **Detailed Description of the Invention**

The present inventors have demonstrated the use and effectiveness of RAR antagonists to stimulate chondrogenesis and skeletal development.

#### **Limb Bud Development**

Patterning of the vertebrate limb bud relies on the cooperative action of several signalling centres. Signals have been identified that emanate from the apical ectodermal ridge (AER), ventral ectoderm (VE) and a region within the distal posterior margin termed the zone of polarizing activity (ZPA). The AER is important in specifying proximodistal axial identity, while the VE and ZPA are important in determining dorsal/ventral and anteroposterior identity, respectively. Each is essential for the proper patterning and outgrowth of the limb, and their perturbation results in defects of the paraxial skeleton. The mechanism by which these patterning cues influence mesenchyme commitment is thought to occur within the progress zone (PZ) which underlies the AER. Cells within the progress zone receive signals from all three signaling centres, integrating them into a positional identity that is fixed as the

cells leave the PZ during limb outgrowth. Shortly thereafter this positional identity is translated into a cell identity and the corresponding differentiation program is initiated. With respect to skeletal formation, these signals culminate in the commitment of mesenchymal cells to the chondrocytic lineage.

5        Bones within the limb are formed from a cartilage precursor and the cartilage forms from condensed mesoderm. These condensations represent the earliest stages of limb patterning and are considered to be the forbears of the mature limb bones (Ede, 1983). Following condensation, the mesodermal cells in the interior of each condensation differentiate into chondrocytes. This differentiation occurs in concert  
10       with limb outgrowth, such that proximal mesenchymal cells (close to the body wall) that are fated to become chondrocytes differentiate prior to more distal cells. The spatiotemporal regulation of mesenchyme differentiation into chondrocytes is a crucial step in endochondral bone formation in that it preserves the pattern of the bone primordia established earlier in limb development and provides a suitable matrix for  
15       subsequent ossification. Despite the importance of this stage in skeletal development, mechanisms that control mesenchyme differentiation into chondrocytes are poorly understood.

During limb outgrowth, signals that promote as well as inhibit chondrogenesis are important determinants in limb ontogeny (Wolpert, 1990). Many molecules have  
20       been identified that promote chondrogenesis *in vivo* and *in vitro*. Some of these include members of the transforming growth factor (TGF)- $\beta$  superfamily, bone morphogenetic proteins (BMPs), *gdf-5*, and TGF- $\beta$  -1, -2 and -3 (Hogan, 1996; Kingsley, 1994; Moses and Serra, 1996; Wozney and Rosen, 1998). The importance of *bmp-5* and *gdf-5* in limb development is illustrated by the recent mapping of the  
25       classical mouse mutations for short ear and brachypod to their respective loci (Kingsley et al., 1992; Storm et al., 1994). Both of these mutants exhibit malformations in appendicular skeletal formation which, for the case of brachypod, has been attributed to a defect in chondrogenesis (Duke and Elmer, 1977). Mice deficient in BMP-6 or BMP-7 also present with skeletal defects including delay in the  
30       ossification of the sternum in *bmp-6* *-/-* animals (Solloway et al., 1998) and polydactyly in the hind limbs of *bmp-7* *-/-* animals (Luo et al., 1995). *Bmp-2* and -4 are expressed in condensing mesenchyme early in limb development then become

localized to the interdigital mesenchyme and perichondrium (Jones et al., 1991; Lyons et al., 1990; Rosen et al., 1989). Mouse embryos devoid of BMP-2 or BMP-4 do not survive beyond E9.5 (Winnier et al., 1995; Zhang and Bradley, 1996) making it difficult to elucidate their exact roles in skeletal development. It is known, however, that exogenously added BMP-2 or -4 under certain circumstances leads to overgrowth of the limb cartilages (Duprez et al., 1996; Duprez et al., 1996). Loss or gain-of-function of noggin, an inhibitor of BMP-2, -4 and -7, contributes to either overgrowth or a reduction in limb cartilages, respectively (Brunet et al., 1998; Capdevila and Johnson, 1998). Together, these observations suggest an important role for the BMPs, especially BMPs -2 and -4 in formation of the cartilaginous elements of the limb bud.

It is well established that retinoic acid (RA), the active derivative of vitamin A is essential for normal embryonic development. Exposure of embryos to excess RA results in a range of defects depending not only on the dose of RA, but also on the timing of its administration (Shenefeldt, 1972). For instance when administered to E 11.5 to E 14.5 mouse embryos, large doses of RA cause limb defects (Kochhar, 1973; Kwasigroch and Kochhar, 1980). This period during which RA treatment has the most dramatic effects on limb formation coincides with the timing of chondrogenesis in the limb bud.

RA exerts most of its biological effects primarily through receptors belonging to the steroid hormone family of nuclear receptors. There are two subfamilies of nuclear retinoid receptors, the RA receptors (RARs) and the retinoid X receptors (RXRs), with three subtypes of each ( $\alpha$ ,  $\beta$ , and  $\lambda$ ) (Chambon, 1996; Mangelsdorf et al., 1994). All three subtypes of the RARs have been suggested to have some role in chondrogenesis (Underhill and Weston, 1998). The expression patterns of the RARs in the developing limb are consistent with their proposed roles in skeletal formation. Between E9.5 and E11.5, RAR $\alpha$  and  $\lambda$  are expressed throughout the limb mesenchyme (Dolle et al., 1989; Ruberte et al., 1990). Beyond this stage, RAR $\alpha$  is downregulated within the cartilaginous areas, while RAR $\lambda$  expression remains localized to these areas. RAR $\alpha$  expression becomes restricted to the interdigital region (IDR) overlapping with RAR $\beta$  expression at this time, and is also present in

the perichondrium. In addition to being present in the IDR, RAR $\beta$  is expressed in the interior, anterior, and posterior necrotic zones (Dolle et al., 1989; Mendelsohn et al., 1991). While null mutants of either RAR $\alpha$ , RAR $\beta$  or RAR $\lambda$  exhibit no limb skeletal malformations (Ghyselinck et al., 1997; Lohnes et al., 1993; Lufkin et al., 1993; Luo et al., 1995), compound homozygous null alleles of RAR $\alpha$  and RAR $\lambda$  exhibit a range of severe limb abnormalities from reductions to duplications (Lohnes et al., 1994). Thus, these results demonstrate an important function for the RARs in skeletal development.

To further explore RAR function in limb development the present inventors have used an existing transgenic line of mice that overexpress a weak constitutively active RAR $\alpha$ 1 (caRAR $\alpha$ ) in the developing limb bud (Cash et al., 1997). Transgenic animals present with a number of limb skeletal abnormalities as a result of transgene-mediated inhibition of cartilage formation. Transgene-expressing cells do not differentiate into chondroblasts, but instead remain as condensed mesenchyme. Conversely, an RAR $\alpha$  antagonist was demonstrated to stimulate cartilage formation in wild-type limb mesenchymal cultures. Addition of BMP-2 or -4 to *in vitro* cultures of transgenic mesenchyme dramatically stimulated condensation of transgene-expressing mesenchymal cells but failed to induce chondroblast differentiation. More importantly, addition of this antagonist was found to rescue chondrogenesis in noggin treated wild-type cultures. Taken together, the results demonstrate that loss of RAR activity is necessary, and supersedes the requirement of BMPs, for chondroblast differentiation during limb outgrowth.

Regulation of chondroblast differentiation is critical for the proper formation of the appendicular skeleton. Herein it is now demonstrated that RAR activity has a fundamental role in controlling the transition of prechondrogenic cells to chondroblasts, and that the loss of RAR activity stimulates cartilage formation. The importance of RARs in mediating chondroblast differentiation is further exemplified by the observations that addition of BMP-2 and -4 is not sufficient to rescue RAR $\alpha$  expressing prechondrogenic cells, while an RAR $\alpha$  specific antagonist is able to rescue cartilage formation in noggin-treated cultures. Therefore, BMPs and RARs function

in a sequential manner to orchestrate chondroblast differentiation during limb bud outgrowth.

#### Function of RARs during skeletal development

- 5 Overexpression of a caRAR $\alpha$  in limb mesenchyme inhibits chondroblast differentiation and maintains the prechondrogenic cell phenotype. The phenotype of cells expressing the transgene is consistent with that of condensed mesenchymal cells and perichondrial cells. Both of these cell types are similar in that they are chondroprogenitors which have not yet undergone chondroblast differentiation.
- 10 Condensed mesenchymal cells and perichondrial cells both have continued expression of N-cadherin, gli-1, and col-I but express col II only weakly, a pattern of expression that is seen in transgenic cultures. The normal expression pattern of RAR $\alpha$  in the developing limb is consistent with its absence being essential for the transition from a chondroprogenitor to a chondroblast. RAR $\alpha$  is expressed in the prechondrogenic
- 15 condensations, the perichondrium, and in the interdigital region, but is downregulated in newly formed cartilaginous elements. The importance of the loss of RAR $\alpha$  signal is further demonstrated by experiments in which the RAR $\alpha$  specific antagonist AGN194301 increased cartilage nodule formation in primary cultures by 60%. Hence, the proper regulation of RAR $\alpha$  activity is essential for normal cartilage development.
- 20 Surprisingly, RAR $\alpha$  null mutants display no overt skeletal malformations of the appendicular skeleton with the exception that a certain proportion (approx. 60% of animals surviving to 1-2 months of age) of RAR $\alpha$  null mutants have webbed digits (Lohnes et al., 1993; Lufkin et al., 1993). However, in micromass cultures, attenuation of RAR $\alpha$ 2 expression with an anti-sense oligonucleotide to RAR $\alpha$ 2
- 25 stimulated cartilage formation *in vitro* (Jiang et al., 1995). This suggests that RAR $\alpha$  alone is not essential for the maintenance of the prechondrogenic cell fate, but one of the RARs may be able to substitute for this function, the most likely candidate being RAR $\gamma$ . RAR $\gamma$  null mutants also have no obvious appendicular skeletal malformations. RAR $\alpha$ /RAR $\gamma$  compound homozygous mutants, however, exhibit a
- 30 number of skeletal defects including reductions, duplications, and to a lesser extent, ectopic cartilage formation within the interdigital region (Lohnes et al., 1994).



Ectopic cartilages are also observed at a number of additional sites in these animals including the meninges, peritoneum, diaphragm, and semi-lunar cusps of the heart (Lohnes et al., 1994; Mendelsohn et al., 1994). In addition, the phalangeal joints of these animals are malformed. While  $RAR\alpha/\beta$  and  $RAR\beta/\gamma$  double knockouts exhibit  
5 some cartilaginous deficiencies, they do not present with any appendicular skeletal defects. More importantly, the skeletal defects in the  $RAR\alpha/\gamma$  double knockouts can be rescued, for the most part, by the single allele of  $RAR\alpha2$ .

Results from knockout studies combined with the *in vivo* expression patterns of RARs suggest that both  $RAR\alpha$  and  $RAR\gamma$  are important in regulating chondroblast  
10 differentiation in the limb.  $RAR\beta$  knockouts exhibit no skeletal abnormalities, and  $RAR\beta$  mRNA is absent in precartilaginous condensations during limb ontogeny (Ghyselinick et al., 1997). Thus, the combined activity of  $RAR\alpha$  and  $RAR\gamma$ , but not  $RAR\beta$  is likely involved in regulating cartilage differentiation in the limb bud. In other areas of the developing embryo, chondrogenesis may also rely on the actions of  
15 specific combinations of RARs.

#### Sequential action of BMPs and RARs in skeletal development

The BMPs have been shown to be important in many aspects of endochondral bone formation including the commitment and differentiation of mesenchymal cells to  
20 the chondrocytic lineage. During limb outgrowth *bmp-2/-4* are expressed within the condensing mesenchyme, the perichondrium and the interdigital region (Jones et al., 1991; Lyons et al., 1990; Rosen et al., 1996). Unfortunately, null mutants have not been informative in sorting out the function of BMPs-2/-4 in these regions (Winnier et al., 1995; Zhang and Bradley, 1996). Additional studies, utilizing dominant-negative  
25 or constitutively active BMP type II receptors *in vitro* and *in vivo* have demonstrated, however, that BMP signaling (most likely BMP-2 and 4) is a requisite step in cartilage formation (Zou et al., 1997). These observations have been complemented by experiments in which BMPs were overexpressed in the developing chick limb. It has been demonstrated that the BMPs can stimulate cartilage formation (Duprez et al.,  
30 1996; Duprez et al., 1996) and modify skeletal element patterning in addition to stimulating apoptosis within the interdigital region (Macias et al., 1997; Yokouchi et

al., 1996). Furthermore, loss or gain of function studies with noggin, an inhibitor of BMP-2 and -4 with lower affinity for BMP-7, has shown that BMP-2 and -4 are important in skeletal development and that regulation of BMP signaling is required for delineation of the various skeletal elements (Brunet et al., 1998; Capdevila and Johnson, 1998). As described herein, exogenously added noggin inhibits cartilage formation in micromass cultures. BMP-2 has been shown to stimulate the commitment and differentiation of pluripotent mesenchymal cells to the chondrocytic lineage (Ahrens et al., 1993; Wang et al., 1993). Thus, BMPs, especially -2/-4, are important in early skeletal development, and appear to have properties consistent with a functional importance in commitment and differentiation of mesenchymal cells to chondrocytes.

Overexpression of a caRAR $\alpha$  prevents prechondrogenic cell differentiation, even in the presence of BMP-2 or -4. Both BMP-2 and -4 enhance the expression of the prechondrogenic phenotype by stimulating the formation of numerous condensations as confirmed by magenta-gal staining and by in situ hybridization with probes for N-cadherin, gli-1, col-I and col-II. Nonetheless, neither BMP-2 nor BMP-4 was able to induce chondroblast differentiation of transgene-expressing cells. These results demonstrate that the regulation of RAR activity operates downstream of BMP-signaling in the chondroblast differentiation sequence. Additional evidence to suggest this comes from the observations that inhibition of cartilage formation by noggin can be circumvented by treatment of cultures with an RAR antagonist. During paraxial development, RAR $\alpha$ , RAR $\gamma$ , are co-expressed in the condensing mesenchyme and in the perichondrium, which are both targets of BMP-2 and -4. Hence, these results suggest that during limb outgrowth BMP-2 and -4 are important in stimulating prechondrogenic cell condensation, whereas a loss of RAR $\alpha$  activity is important in allowing the differentiation of these cells. In this manner, the BMP and RA-signaling pathways may function sequentially in the commitment and differentiation of mesenchymal cells, respectively, during limb outgrowth.

RAR function in chondroblast differentiation: Conservation in other developmental processes

A similar hierarchy of BMP and RA signaling may be operating in other developmental processes. BMPs-2 and -4 and RARs are co-expressed in a number of different regions within the developing embryo. As mentioned previously, BMP-2 and -4 are co-expressed with RAR $\alpha$ ,  $\beta$ , and  $\gamma$  in the interdigital region. Application of BMPs to the interdigital region enhances interdigital apoptosis (Macias et al., 1997; Yokouchi et al., 1996), while overexpression of a dominant-negative BMPRIIR inhibits interdigital apoptosis and webbed digits (Zou and Niswander, 1996; Zou et al., 1997). In addition, loss of RAR $\alpha$ , or loss of  $\beta$  and  $\gamma$  together, leads to a cessation of interdigital apoptosis and webbed digits. When cultured prior to the initiation of apoptosis, explants of the interdigital region will form cartilage unless RA is present in which case they will undergo apoptosis (Lee et al., 1994). Similarly, addition of RA to *in vitro* cultured limbs stimulates regression of the interdigital regions (Lussier et al., 1993). Together, these observations suggest that the BMPs and RA-signaling pathways coordinate interdigital cell death, in addition to chondrogenesis.

During heart formation BMP-2 and -4 appear to be important in specifying ventricular cardiomyocytes whereas the RARs regulate the differentiation of this population of cells. Loss of RAR activity through inactivation of RXR $\alpha$ , RXR $\beta$ , RAR $\alpha$  causes precocious differentiation of ventricular myocytes (Kastner et al., 1997). Hence, RARs are functioning in the heart to regulate progenitor cell differentiation as they do within the limb.

One of the functions of RARs in limb development is to regulate the differentiation of skeletal progenitor cells. In this manner, RAR activity may specify the size of progenitor cell populations, and/or influence cell fate decisions by modulating the competency of cells to respond to inductive signals, such as BMPs. The status of cellular RAR activity, therefore, appears to be an important determinant in the spatiotemporal regulation of cell differentiation in the developing limb, heart and spinal cord.

#### RAR Antagonists

With the demonstration that RAR antagonist compounds can act as potent stimulators of chondrogenesis and associated skeletal development, various therapeutic *in vivo* and *in vitro* uses of such antagonists are now made possible

especially those uses involving abnormal chondrogenesis and related skeletal development.

The RAR antagonist AGN 194301, shown in Table 1, has been demonstrated to stimulate cartilage formation and promote chondroblast differentiation. AGN 194301 (2-Fluoro-4-[(1-(8-bromo-2,2-dimethyl-4-(4-methylphenyl)-2-*H*-chromen-6-yl)-methanoyl)-amino]-benzoic acid) is a potent antagonist of RAR $\alpha$ , with a high affinity for that receptor. It has a lower affinity for RAR $\beta$  and RAR $\gamma$ , but does also act as an antagonist of these receptors.

In accordance with one embodiment of the invention, chondrogenesis-stimulating RAR antagonists comprise antagonist compounds which are highly effective against RAR $\alpha$  and also antagonise RAR $\beta$  and RAR $\gamma$ . Thus, the present invention encompasses RAR antagonists in general and any agent which demonstrates RAR antagonist activity. Those of ordinary skill in the art are able to screen candidate compounds to identify compounds having such an RAR antagonist profile by methods available in the scientific literature, for example as described in Teng et al., (1997), *J. Med. Chem.*, 40, 2445-2451.

In accordance with one embodiment of the invention, chondrogenesis-stimulating RAR antagonists comprise mono- or di-fluoro substituted methylchromenes such as AGN 194301. The RAR antagonist compounds of the invention may be synthesized by conventional chemical synthetic methods. For example, AGN 194301 may be synthesised as described in Teng et al., (*supra*). In some cases, suitable RAR antagonists may be purchased.

One skilled in the art would readily understand that several different types of RAR antagonists other than those described specifically herein are suitable for use in the present invention. Other suitable RAR antagonists are taught for example in WO 9933821, WO 9924415, U.S. 5,877,207 and JP 10114757. Such antagonist agents include but are not limited to AGN 193109, AGN 190121, AGN 194574, AGN 193174, AGN 193639, AGN 193676, AGN 193644, SRI 11335, Ro 41-5253, Ro 40-6055, CD 2366, BMS 185411, BMS 189453, CD-2665, CD 2019, CD 2781, CD 2665, CD 271. Other suitable RAR antagonists for use in the present invention include those disclosed in Kaneko et al., 1991; Apfel et al., 1992; Eyrolles et al., 1994; Yoshimura et al., 1995; Eckharat and Schmitt, 1994; and Teng et al., 1997.

The chondrogenesis-stimulating RAR antagonists of the invention are useful for the treatment and management of skeletal problems or abnormalities resulting from disease or trauma in vertebrates, including humans and other mammals, including horses. They may be used in several therapeutic applications where  
5 increased chondrogenesis is desired and also for stimulation of skeletal development.

Therapeutic applications of these antagonists include the stimulation of new cartilage formation and accelerate associated bone repair through endochondral ossification.

A pharmaceutical composition comprising at least one chondrogenesis-  
10 stimulating RAR antagonist may be applied locally to a fracture site, for example by means of a biodegradable sponge, gel, coating or paste. A suitable gel for use would be a collagen type gel such as collagen I.

The antagonists of the present invention may also be used for the treatment of orthopedic or dental implants to enhance or accelerate osseous integration. A  
15 pharmaceutical composition comprising at least one chondrogenesis-stimulating RAR antagonist may be directly applied locally to the site of desired osseous integration or alternatively as a coating on implants.

The RAR antagonists may also be used for promoting *in vivo* integration of implantable prosthetic devices. In general, the RAR antagonist compositions of the  
20 invention may be applied to synthetic bone grafts for implantation whereby the antagonist composition stimulates cartilage formation and indirectly bone formation. The compositions thus have numerous applications in the orthopedic industry. In particular, there are applications in the fields of trauma repair, spinal fusion, reconstructive surgery, maxillo-facial surgery and dental surgery. The ability of the  
25 RAR antagonist compositions to stimulate local natural bone growth provides stability and rapid integration, while the body's normal cell-based bone remodeling process slowly resorbs and replaces a selected implant with natural bone. Implants suitable for *in vivo* use are generally known to those skilled in the art.

The RAR antagonists of the invention may be used for cartilage and skeletal reconstruction. In such an application, the antagonists can be used for *ex vivo* tissue engineering of cartilage or skeletal tissue for implantation in a vertebrate. Cells can be treated with a RAR antagonist during osteochondral autograft or allograft transplantations (Minas et al., (1997), Orthopedics, 20, 525-538). In autograft transplantations, chondrogenic cells or cells with chondrogenic potential are removed from a patient (e.g. from a rib) and used to fill a cartilaginous lesion. An alternative method involves expanding these cells *in vitro*, then implanting them into a cartilaginous lesion. A pharmaceutical composition comprising at least one chondrogenesis-stimulating RAR antagonist would be used to treat the cells in *in vitro* culture prior to engraftment and/or after engraftment through intra-articular injection. The use of the RAR compositions of the invention may eliminate the pain and costs associated with the bone harvest procedure required in autograft transplants. Furthermore, the RAR compositions can be made synthetically thus reducing the possibility of transmission of infection and disease, as well as diminishing the likelihood of immunological rejection by the patient.

The antagonist compositions of the present invention may also be used for the treatment of arthritis, either osteoarthritis or other types of arthritis including rheumatoid arthritis. To reverse or slow degenerative joint disease characterized by cartilage degeneration, a pharmaceutical composition comprising at least one chondrogenesis-stimulating RAR antagonist would be applied locally through intra-articular injection or in combination with a viscosupplement. The composition could be provided in either a fast-release or slow-release formulation. Such compositions have use in patients with degenerative hip or knee joints, for example.

In general, the RAR antagonists may be used to stimulate *in vitro* chondrogenesis from mesenchymal precursor cells and *in vitro* formation of chondrocytes. Such cell culture materials and methods are known to those skilled in the art and are also described herein in the examples. Cells and tissues treated with a selected RAR antagonist *in vitro* can be used therapeutically *in vivo* or alternatively for *in vitro* cellular assay systems.

The pharmaceutical compositions of the invention may be used in combination with other chondrogenic stimulators, e.g. bone morphogenetic proteins (BMPs)

especially BMP-2 and BMP-4, osteogenic proteins (OPs) such as OP-1 and/or cytokines to enhance and/or maintain the effects of the compositions. Both BMPs and OPs are proteins belonging to the TGF- $\beta$  superfamily which represent proteins involved in growth and differentiation as well as tissue morphogenesis and repair. It is also understood that the RAR antagonist compositions of the invention may additionally comprise other chondroinductive agents or factors, defined as any natural or synthetic organic or inorganic chemical or biochemical compound, or mixture of compounds which stimulate chondrogenesis. It is further understood that the RAR antagonist compositions of the invention may also comprise other growth factors known to have a stimulatory effect on cartilage growth and formation.

The RAR antagonist compositions described herein appear to have a more dramatic effect on chondrocyte function than the BMPs and show longer-lived effects. The RAR antagonists are also more cost effective to manufacture than BMPs.

Those of ordinary skill in the art are familiar with various methods of formulating pharmaceutical compositions for local administration in diseases such as arthritis. For example, Adams et al., (1995), *Osteoarthritis & Cartilage*, 3, 213-225, describes viscosupplementation in osteoarthritis; Wozney et al., (1998), *Clin. Ortho. Rel. Res.*, 346, 26-37, describes delivery methods used for BMPs to effect bone repair and formation. These formulation methods may be employed to prepare the RAR compositions of the invention.

For therapeutic applications in accordance with the present invention the RAR antagonists are incorporated into pharmaceutical compositions formulated for oral or parenteral administration, the latter route including intravenous and subcutaneous administration. Parenteral administration may be by continuous infusion over a selected period of time. As such, the compositions may be provided as tablets, pills, capsules, solutions, suspensions, creams, gels, and the like.

An RAR antagonist may be orally administered with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, compressed into tablets or incorporated directly with the food of the diet.

For oral therapeutic administration, the RAR antagonist may be incorporated with excipient and used in the form in ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.

In one embodiment of the present invention, a pharmaceutical composition for administration to subjects in a biologically compatible form suitable for administration *in vivo* for treating abnormal chondrogenesis and associated skeletal development comprises a safe and effective amount of a selected RAR antagonist alone, or in combination with other agents and/or pharmaceutically acceptable carriers. The composition may be administered to any living organism including humans and animals. By "safe and effective amount" as used herein is meant providing sufficient potency in order to decrease, prevent, ameliorate or treat a chondrogenesis or skeletal disorder affecting a subject while avoiding serious side effects. A safe and effective amount will vary depending on the age of the subject, the physical condition of the subject being treated, the severity of the disorder, the duration of treatment and the nature of any concurrent therapy. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. The compositions are preferably in the form of a unit dose and will usually be administered as a dose regimen that depends on the particular tissue treatment.

The compositions described herein can be prepared by known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable carrier. By pharmaceutically acceptable carrier as used herein is meant one or more compatible conventional solid or liquid delivery systems as are well known in the art. Some examples of pharmaceutically acceptable carriers are sugars, starches, cellulose and its derivatives, powdered tragacanth, malt, gelatin, collagen, talc, stearic acids, magnesium stearate, calcium sulfate, vegetable oils, polyols, agar, alginic acids, pyrogen-free water, isotonic saline, phosphate buffer, and other suitable non-toxic substances and medicinal agents used in pharmaceutical formulations. Other excipients such as wetting agents and lubricants, tableting agents, stabilizers, anti-oxidants and preservatives are also contemplated. Suitable carriers are further described for example in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis the compositions include, albeit not



exclusively, solutions of the substance in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

The RAR antagonist compositions of the invention can be provided as a liquid for local administration at a desired tissue site such as by injection. Alternatively, the compositions of the invention can be provided encapsulated for administration to a desired tissue site. In one embodiment, the RAR antagonist composition may comprise at least one RAR antagonist which may be provided as a solution or emulsion contained within phospholipid vesicles called liposomes. The liposomes may be unilamellar or multilamellar and are formed of constituents selected from phosphatidylcholine, dipalmitoylphosphatidylcholine, cholesterol, phosphatidylethanolamine, phosphatidylserine, demyristoylphosphatidylcholine and combinations thereof. The multilamellar liposomes comprise multilamellar vesicles of similar composition to unilamellar vesicles, but are prepared so as to result in a plurality of compartments in which the silver component in solution or emulsion is entrapped. Additionally, other adjuvants and modifiers may be included in the liposomal formulation such as polyethyleneglycol, or other materials.

It is understood by those skilled in the art that any number of liposome bilayer compositions can be used in the composition of the present invention. Liposomes may be prepared by a variety of known methods such as those disclosed in U.S. Patent No. 4,235,871 and in RRC, Liposomes: A Practical Approach. IRL Press, Oxford, 1990, pages 33-101.

The liposomes containing the RAR antagonist may have modifications such as having non-polymer molecules bound to the exterior of the liposome such as haptens, enzymes, antibodies or antibody fragments, cytokines and hormones and other small proteins, polypeptides or non-protein molecules which confer a desired enzymatic or surface recognition feature to the liposome. Surface molecules which preferentially target the liposome to specific organs or cell types include for example antibodies which target the liposomes to cells bearing specific antigens. Techniques for coupling such molecules are well known to those skilled in the art (see for example U.S. Patent 4,762,915 the disclosure of which is incorporated herein by reference). Alternatively, or in conjunction, one skilled in the art would understand that any number of lipids

bearing a positive or negative net charge may be used to alter the surface charge or surface charge density of the liposome membrane.

The liposomes can also incorporate thermal sensitive or pH sensitive lipids as a component of the lipid bilayer to provide controlled degradation of the lipid vesicle membrane.

For systemic application by intravenous delivery, it may be beneficial to encapsulate the RAR antagonist within sterically-stabilized liposomes which exhibit prolonged circulation time in blood. The sterically stabilized liposomes are produced containing polyethylene glycol as an essential component of their surface and the method of making such liposomes is known to those skilled in the art.

The size of the liposomes can be selected based on the intended target and route of administration. Liposomes of between about 10 nm to 300 nm may be suitable. Furthermore, the composition of the present invention may include liposomes of different sizes.

While the composition of the present invention may be encapsulated for administration by liposomes, it is understood by those skilled in the art that other types of encapsulants may also be used to encapsulate the RAR antagonist. Microspheres including but not limited to those composed of ion-exchange resins, crystalline ceramics, biocompatible glass, latex and dispersed particles are suitable for use in the present invention. Similarly, nanospheres and other lipid, polymer or protein materials can also be used.

The RAR antagonist compositions of the present invention may comprise a RAR antagonist dispersed in an implantable biocompatible carrier that functions as a suitable delivery or support system for the antagonist. Suitable examples of biocompatible sustained release carriers include semi-permeable polymer matrices in the form of shaped implantable articles such as polylactides, copolymers of L-glutamic acid, ethyl-L-glutamate, poly(2-hydroxyethyl-methacrylate) or ethylene vinyl acetate. Such matrices can be fabricated to have the RAR antagonist incorporated therein and be of a selected pore size to permit chondroprogenitor cells and skeletal progenitor cells to migrate within. The selected carrier material may also comprise a biodegradable, synthetic or synthetic-organic matrix such as hydroxyapatite, collagen, tricalcium phosphate or various copolymers of glycolid, lactic and butyric acid.

The RAR antagonist composition of the present invention may also be used with demineralized allogenic bone and demineralized xenogenic bone optionally treated with fibril modifying agents. Furthermore, the composition may be provided with a mechanical or suitable physical device, influence or force such that it functions to promote chondrogenesis and skeletal development either *in vitro* or *in vivo*.

In summary, RAR antagonists have important clinical therapeutic uses for treatment of cartilage and associated bone development defects. The RAR antagonists can be used to provide such treatment both *in vitro* and *in vivo* to treat a variety of conditions as a result of trauma, genetic disease or degenerative disease negatively affecting cartilage and associated bone development and maintenance.

### EXAMPLES

The examples are described for the purposes of illustration and are not intended to limit the scope of the invention.

Methods of chemistry, protein and peptide biochemistry, cell biology, molecular biology and immunology referred to but not explicitly described in this disclosure and examples are reported in the scientific literature and are well known to those skilled in the art.

### Methods

#### **Preparation of micromass cultures**

Micromass cultures were prepared from murine E11.25 to E11.75 fore and hind limb buds as previously described with the following modifications (Cash et al., 1997). After proteolytic digestion cells were filtered through a Cell Sieve (40 $\mu$ M, Falcon) to obtain a single cell suspension. Culture media (40% Dulbecco's modified Eagle's medium, 60% F12 was supplemented with fetal bovine serum to 10%, Gibco-BRL) was changed daily. BMP-2 or-4 (Genetics Institutes), AGN 194301 (Allergan Pharmaceuticals) and/or purified *Xenopus* noggin protein was added to culture media at a concentration of 10ng/ml, 1  $\mu$ M and 10ng/ml, respectively. Addition/removal experiments included either adding or removing supplemented media on the indicated culture day, 24 hours after culture initiation was considered day 1. To detect transgene-expressing cells, cultures were fixed stained as previously described, with

magenta-gal (BioSynth International Inc.) being substituted for X-gal. This was followed by alcian blue staining for cartilage-specific glycosaminoglycans. Alcian blue staining of magenta-gal stained cultures turned the red precipitate to a purple color, this is a result of incubating magenta-gal stained cells at pH 1. This double-staining technique enables transgene-expressing cells to be localized with respect to alcian blue stained cartilage nodules.

### Synthesis of Riboprobes

Riboprobes were synthesized in the presence of UTP-digoxigenin with the appropriate RNA polymerase and linearized template DNA according to the manufacturers directions (Boehringer Mannheim Corp., Indianapolis, IN). Riboprobe complementary to collagen type II gene, was generated from Bam H1 linearized pBluescript containing 1.1kb of the collagen type II gene containing the C-propeptide and transcribed *in vitro* with T7 RNA polymerase. Gli-1 riboprobe was transcribed from Not I linearized pBluescript containing a 1.6 kb fragment representing most of the zinc finger domain of gli-1. A 553 bp fragment of murine collagen type I (Phillips et al., 1992) was subcloned into pKS II (Stratagene), this was linearized with XhoI and transcribed with T7 RNA polymerase. A Hind III (position 605) -BamHI (position 1252) fragment from the mouse N-cadherin cDNA was subcloned into pKSII. This construct was linearized with Bam H1 and riboprobe synthesized with T7 RNA polymerase. For controls, sense riboprobes were synthesized from the aforementioned plasmids.

### Whole-Mount *In situ* Hybridization of Micromass Cultures

*In situ* hybridizations were carried out on micromass cultures using a technique described previously (Cash et al., 1997), with minor modifications. After permeabilization using 10 µg/ml proteinase-K in phosphate buffered saline (PBS) supplemented with 0.05% Triton X-100, cells were post-fixed in 4% paraformaldehyde and 2% glutaraldehyde in PBS and hybridizations were carried out at 60°C instead of 55°C.

### Transient Transfection Analysis

The ability of AGN194301 to inhibit all-trans RA induction of an RARE containing luciferase construct was performed in P19 embryonal carcinoma cells as previously described with some modification (Underhill et al., 1994). P19 cells were seeded at a density of  $1.5 \times 10^4$  cells/well in 6 well plates. Cells were transfected using the calcium phosphate precipitation method with each well receiving 3.9  $\mu$ g DNA (1.25  $\mu$ g pW1RAREtk-lucif, 0.33 $\mu$ g pW1ActRAR $\alpha$ / $\beta$ / $\gamma$ , .67  $\mu$ g pW1Act $\beta$ -galactosidase and 1.65 $\mu$ g pGEM9zf(-)). Following transfection cells were washed and fresh media was added that contained  $1 \times 10^{-7}$  M all-trans RA and various amounts of AGN194301. Twenty-four hours later cell extracts were prepared, and luciferase and  $\beta$ -galactosidase activity measured. Luciferase activity was normalized with  $\beta$ -galactosidase activity to control for differences in transfection efficiency.

#### Northern Blot Analysis

Total RNA was isolated dissected and pooled limb buds from wild-type and transgenic embryos at various gestational stages with TriPure Isolation Reagent (Boehringer Mannheim). RNA samples were separated by electrophoresis of 15  $\mu$ g aliquots in a 1% agarose-formaldehyde gel. RNA was then transferred to a Hybond-N nylon membrane (Amersham Life Science) and cross-linked by UV irradiation. Blots were pre-hybridized in Church's Buffer (7% SDS, 0.5 M NaPi pH 7.2, 1mM EDTA, 1% BSA) at 65° C for at least 30 min. Radiolabeled DNA probes were synthesized by random priming using standard methods with the appropriate cDNA insert fragments. Hybridizations were carried out overnight at 60° C. Following hybridization blots were washed with wash buffer (250mM NaPi, 10% SDS) three times for 15 min. at 65°C, and exposed to BioMax X-ray film at -80°C for 1-4 days.

#### Example 1: Transgene-expressing cells do not contribute to cartilage nodule formation

To further demonstrate the role of the RARs, specifically RAR $\alpha$ , during cartilage formation, we used a previously described transgenic mouse model (Cash et al., 1997). Overexpression of a weak constitutively active RAR $\alpha$  during limb development leads to various congenital malformations of the limb that are

reminiscent of those observed in RA teratogenicity. During chondroblast differentiation, RAR $\alpha$  expression is down-regulated. The continued expression of RAR $\alpha$  inhibits chondroblast differentiation leading to a cessation of cartilage formation and to skeletal deficiencies as observed in the transgenic mice. Limb mesenchyme from embryonic age (E) 11.5 transgenic embryos was used to set up micromass cultures to examine the cell fate of transgene-expressing cells during *in vitro* chondrogenesis. Shown in figure 1 is a time-course of cartilage nodule formation (day-2, day-4 and day-6) in wild-type (figure 1A, B, and C) and transgenic fore limb cultures (figure 1E, 1F, 1G) and hind limb cultures (figure 1H, day-4 shown). Consistent with previous observations there are many fewer alcian blue-stained nodules in the transgenic derived cultures than in the wild-type cultures. Using a combination of magenta-gal and alcian blue staining, we clearly show that transgene-expressing cells are, for the most part, excluded from the cartilage nodules (figure 1D) but appear to form condensations. Transgene-expressing cells fail to differentiate into chondroblasts in contrast to both non-transgene-expressing cells within the same cultures, and cells within wild-type cultures.

#### **Example 2: Transgene-expressing cells have a prechondrogenic phenotype**

Cartilage formation involves two well described steps: 1) condensation of mesenchymal cells; 2) differentiation of condensed mesenchyme to matrix-producing chondrocytes (Hall and Miyake, 1992). These two stages can be distinguished based on histological staining, however, using molecular markers is generally a more reliable method for determining the phenotype of cells at either stage. Previous studies have shown that condensed prechondrogenic cells express col II weakly and express N-cad, col I and gli-1 abundantly (Hall and Miyake, 1995; Marigo et al., 1996; Oberlender and Tuan, 1994). Upon differentiation of these cells, col II expression becomes much stronger, whereas expression of N-cad, col I, and gli-1 are downregulated. To further characterize the phenotype of the transgene-expressing cells, whole mount *in situ* hybridization was carried out to examine the expression patterns of col II, N-cad, col I and gli-1 in transgenic and wild-type cultures. In wild-type cultures, col II expression was very strong and localized primarily to the core of the cartilage nodules with weaker expression in regions surrounding the

nodules (figure 2A). Expression of N-cad, col I and gli-1 in wild-type cultures was restricted to perinodular regions in condensed mesenchyme and was weakly expressed in the centre of the nodules (figure 2C, E and G). The expression patterns of these genes in the wild-type cultures is consistent with their expression *in vivo*. In transgenic cultures, however, their expression patterns would indicate that while condensations are present the condensed cells have not yet differentiated. There was no downregulation of N-cad, col I or gli-1, instead they were expressed throughout the condensations (figure 2D, F and H), whereas col II was only weakly expressed (figure 2B), resembling a pattern one would expect to see in condensations but not in cartilage nodules. These observations demonstrate that the transgene-expressing cells condense but do not undergo chondroblast differentiation.

Comparison of the distribution of col II expression in transgenic and wild-type cultures suggests that the transgenic cultures form a similar number of condensations as observed in wild-type cultures (figure 2A, B). Furthermore, the col II stained regions in transgenic and wild-type cultures are similar in size indicating that transgene-mediated inhibition of chondroblast differentiation was not a consequence of insufficient numbers of prechondrogenic cells (Hall and Miyake, 1992). Moreover, during the culture period the transgene-expressing cell aggregates continue to expand in size and staining intensity (figure 1E, 1F and 1G). Northern blot analysis has confirmed differential expression of col II and gli-1 between the hind limbs of wild-type and transgenic mice. By E 14.5, col II is downregulated in transgenic hind limbs (Figure 2I), whereas gli-1 is downregulated in transgenic hind limb at E 12.5 (Figure 2I). The *in situ* hybridization results combined with results from Northern blot analysis demonstrate that the phenotype displayed by transgene-expressing cells is consistent with condensed prechondrogenic cells.

### **Example 3: Transgene-expressing cells are refractile to BMP-stimulated chondroblast differentiation**

To further investigate the mechanism of transgene-mediated inhibition of chondroblast differentiation, the expression of genes known to be important in chondrogenesis, namely the BMPs was examined. Based on their expression in limb development and their well defined chondrogenic stimulatory properties, the analysis

was focused on *bmps-2* and *-4*. Hence, one plausible explanation for the transgenic phenotype was either the reduced expression of *bmps* or overexpression of *noggin* which encodes an inhibitor of BMP signaling. Northern analysis using mRNA from hind limbs of transgenic and wild-type animals at E 11.5, 12.5, and E 14.5 demonstrated that neither *bmp2* nor *noggin* is differentially expressed in transgenic animals in comparison to wild-type animals (data not shown). The defect in transgenic limb mesenchyme therefore is not likely a result of changes in expression of either of these two transcripts. However, these results do not preclude the possibility that transgene-expressing mesenchymal cells are unresponsive to BMPs.

To evaluate whether transgene-expressing cells are able to respond to BMPs, transgenic and wild-type micromass cultures were treated with 10 ng/ml BMP-2 and -4. It was demonstrated that addition of BMP-2 (figure 3A) and -4 dramatically increases the number of cartilage nodules in wild-type and transgenic cultures. BMP-2 treatment for six days increased the number of cartilage nodules by ~125% and ~115% in wild-type and transgenic fore limb cultures, respectively (figure 3A-I). Hence, addition of BMP-2 or -4 appears to rescue the chondrogenic defect present in transgenic cultures. To confirm this, BMP-2 treated cultures were stained with magenta-gal followed by alcian blue (figure 3F, G and H). As observed in non-treated transgenic cultures, few if any transgene-expressing cells were found to be present within the alcian blue stained cartilage nodules (figure 3I). Addition of BMP-2, however, stimulated condensation of transgene-expressing cells (figure 3F-I). This was confirmed by *in situ* hybridization, BMP-2 addition stimulated the formation of col II expressing nodules and weak col II condensations in wild-type and transgenic cultures, respectively (Figure 4). Condensations were observed as early as 2 days in culture and were still evident after 6 days in culture. Thus, although BMP-2 or -4 induces transgene-expressing cells to form precartilaginous condensations they are not sufficient to overcome transgene-mediated inhibition of prechondrogenic cell differentiation.

#### **Example 4: Loss of retinoic acid receptor activity stimulates chondrogenesis**

It has presently been demonstrated that the continued expression of  $RAR\alpha$  inhibits the transition of prechondrogenic cells to chondroblasts. It was then



demonstrated that the abrogation of RAR $\alpha$  activity stimulated chondroblast differentiation and/or cartilage formation. RAR activity as used herein refers to the level of RA-induced transcriptional activity of the RARs. Micromass cultures were treated with the RAR $\alpha$ -specific antagonist AGN194301 to examine whether

5 inhibition of RAR $\alpha$  activity stimulated cartilage formation. Addition of 1  $\mu$ M AGN194301 to wild-type micromass cultures lead to a dramatic increase in nodule number with no apparent increase in nodule size as compared to untreated control cultures (figure 5G, J, M). After 8 days in culture there were 60% more nodules in antagonist treated cultures than in untreated cultures (figure 5M). Similar to the

10 inhibition of cartilage nodule formation observed in response to all-trans RA treatment of micromass cultures, addition of the RAR $\alpha$ -specific agonist AGN 193836 at 1  $\mu$ M, decreased the number of cartilage nodules that formed by 35% with the nodules staining only weakly with alcian blue. To confirm that the concentrations utilized in these experiments inhibited RAR $\alpha$  activity specifically, the level of RAR $\alpha$ ,

15 RAR $\beta$  and RAR $\gamma$  mediated RARE activation was measured with 100nM all-trans RA in the presence of various concentrations of antagonist. At 1  $\mu$ M of AGN194301, RAR $\alpha$  signaling was inhibited to ~0.3% of controls, while RAR $\beta$  and RAR $\gamma$  were inhibited to ~18% and ~26% of controls, respectively. Hence, most of the chondrogenic stimulatory properties of the antagonist appear to be mediated through

20 inhibition of RAR $\alpha$ , however, it cannot be entirely discounted that diminution of RAR $\beta$  or RAR $\gamma$  signaling may have contributed to these results. Nonetheless, loss of RAR activity stimulates cartilage formation while increased RAR activity inhibits cartilage formation.

25 **Example 5: The RAR antagonist and BMP-2 have different chondrogenic stimulatory properties**

The loss of RAR activity and addition of BMP-2 both stimulate cartilage formation. In transgenic cultures, BMP-2 stimulated condensation but not differentiation of transgene-expressing cells, whereas a loss of RAR $\alpha$  activity induced

30 cartilage formation. These results suggest that the two factors: a) BMP-2 availability and b) RAR $\alpha$  activity are important at different stages during chondrogenesis. To

further delineate the role of BMP-2 and RAR $\alpha$  in cartilage formation, we have used an approach that involves incubation of micromass cultures with AGN194301 or BMP-2 for different periods of time during culturing. To accomplish this BMP-2 or AGN194301 were added to cultures for the first 2 or 3 days then removed, or were added after 2 or 3 days of culturing. As has been shown previously (Roark and Greer, 1994), addition of BMP-2 at later culture periods yielded results that are comparable to experiments in which BMP-2 is added continuously from the start of culture (figure 5D-F). Conversely, addition of BMP-2 for the first 2 to 3 days of culture caused an increase in nodule number but this increase was not as dramatic as that observed upon adding BMP-2 later (ie: after 2 or 3 days). The average size of the nodules was also noticeably increased in cultures that were either continuously exposed to BMP-2 or treated after 2 or 3 days of culture (figure 5B-F). These large nodules radiate towards the outside of the culture and are, in part, a consequence of the recruitment of proliferating uncommitted cells present in the periphery of the culture into the nodules. Similar observations have been made with BMP-2 addition *in vivo* as Duprez *et al.* (Duprez *et al.*, 1996) showed that expansion of skeletal elements in the presence of BMP-2 or -4 was at the expense of other cell populations in the developing chick limb bud. Hence, the consequences of BMP-2 addition are much more pronounced in cultures treated at later stages of culture and likely reflect the ability of BMP-2 to stimulate commitment of mesenchymal cells to the chondrocytic lineage with subsequent recruitment into nodules.

In contrast to BMP-2 and -4, AGN194301 had its most pronounced stimulatory effect on nodule formation when it was present early in the culture period. When 1  $\mu$ M AGN194301 was added to cultures for only the first 2 or 3 days, then removed, more cartilage nodules were formed compared to untreated cultures (figure 5G-I) or to cultures exposed for longer periods of time but untreated for the first 2 or 3 days (figure 5K, L). Interestingly, the increase in nodule number caused by early treatment of the antagonist was maintained for 4 or more days after its removal and was comparable to the increase in nodule number observed with continuous treatment (figure 5H-J). AGN194301, therefore, caused an increase in nodule formation, however the nodules were much smaller compared to cultures receiving antagonist at later culture times. When BMP-2 and AGN194301 were added together to

micromass cultures at a concentration of 10ng/ml and 1  $\mu$ M, respectively, there was a ~100% increase in nodule number compared to untreated controls (figure 5M). BMP-2 addition alone to cultures initiated from the same limb buds caused a ~45% increase, whereas AGN194301 treatment caused an increase of ~60% (figure 5M).

Together, these results demonstrate that the loss of RAR activity and the presence of a BMP signal are two events that act at different stages of the chondrogenic sequence as they exhibit markedly different chondrogenic stimulatory properties.

**Example 6: Cartilage formation is rescued in Noggin-treated cultures by addition of an RAR $\alpha$  antagonist**

To further address the requirement for BMPs in chondrogenesis, wild-type limb mesenchyme cultures were treated with Noggin, a secreted inhibitor of BMP-2, and -4. Addition of 10ng/ml Noggin to wild-type cultures dramatically reduced cartilage nodule formation by ~84% in comparison to untreated controls (Fig 6a, b and d). In an attempt to define the chondrogenic stage affected by Noggin, cultures treated with Noggin were examined for the expression of *col II* and *col IIA* an alternatively spliced form of col II expressed in prechondrogenic cells (Sandell, et al., 1991, Sandell, et al., 1994). In limb bud derived cultures *col IIA* is expressed in the condensing mesenchyme surrounding cartilaginous nodules and in precartilaginous condensations (Fig. 6e, f). If Noggin delays or inhibits chondroblast differentiation but does not affect condensation, then the decrease in col II expressing nodules should be accounted for by col IIA expressing condensations. In contrast, however, comparison of expression of these two genes by *in situ* hybridization in Noggin-treated cultures indicates there are no additional condensations present (Fig. 6e, f). Hence, Noggin appears to interfere with formation of precartilaginous condensations.

Earlier experiments in which addition of BMP-2 was unable to rescue cartilage in transgene-expressing cultures coupled with the accelerated appearance of col II expressing cells in antagonist-treated cultures demonstrated that loss of RAR activity alone is sufficient to initiate the chondrogenic differentiation program. To further demonstrate this, Noggin-treated cultures were exposed to the RAR antagonist. The addition of 1  $\mu$ M AGN194301 to Noggin-treated cultures, stimulated cartilage nodule formation such that these cultures resembled untreated cultures

(figure 6a, c and d). In contrast, addition of 10 or 20 nM all-trans RA further diminished nodule formation in Noggin-treated cultures (data not shown). These results indicate that suppression of RAR-mediated signaling not only stimulates expression of the chondrogenic phenotype, but can do so independently of a BMP  
5 signal.

**References**

- Adams, M. E., Atkinson, M. H., Lussier, A. J., Schulz, J. I., Siminovitch, K. A., Wade, J. P., and Zummer, M. (1995). The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. *Osteoarthritis & Cartilage* 3, 213-25.
- Ahrens, M., Ankenbauer, T., Schroder, D., Hollnagel, A., Mayer, H., and Gross, G. (1993). Expression of human bone morphogenetic proteins-2 or -4 in murine mesenchymal progenitor C3H10T1/2 cells induces differentiation into distinct mesenchymal cell lineages. *DNA Cell Biol.* 12, 871-880.
- Amos, B., and Lotan, R. (1990). Retinoid-sensitive cells and cell lines. *Meth. Enz.* 190, 217-225.
- Apfel, C. et al. (1992). Retinoic Acid Receptor alpha Antagonist Selectivity Counteracts Retinoic Acid Effects. *Proc. Natl. Acad. Sci. U.S.A.* 89, 7129-7133.
- Brunet, L. J., McMahon, J. A., McMahon, A. P., and Harland, R. M. (1998). Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton [see comments]. *Science* 280, 1455-7.
- Capdevila, J., and Johnson, R. L. (1998). Endogenous and ectopic expression of noggin suggests a conserved mechanism for regulation of BMP function during limb and somite patterning. *Dev Biol* 197, 205-17.
- Cash, D. E., Bock, C., Schughart, K., Linney, E., and Underhill, T. M. (1997). Retinoic acid receptor alpha function in vertebrate limb skeletogenesis: a modulator of chondrogenesis. *J. Cell Biol.* 136, 445-457.

Chambon, P. (1996). A decade of molecular biology of retinoic acid receptors.  
FASEB J. 10, 940-954.

Dolle, P., Ruberte, E., Kastner, P., Petkovich, M., Stoner, C. M., Gudas, L. J., and  
5 Chambon, P. (1989). Differential expression of genes encoding alpha, beta and  
gamma retinoic acid receptors and CRABP in the developing limbs of the mouse.  
Nature 342, 702-705.

Duke, J., and Elmer, W. A. (1977). Effect of the brachypod mutation on cell adhesion  
10 and chondrogenesis in aggregates of mouse limb mesenchyme. J. Embryol. Exp.  
Morph. 42, 209-217.

Duprez, D., de H. Bell, E. J., Richardson, M. K., Archer, C. W., Wolpert, L., Brickell,  
P. M., and Francis-West, P. H. (1996). Overexpression of BMP-2 and BMP-4 alters  
15 the size and shape of developing skeletal elements in the chick limb. Mechanisms of  
Development 57, 145-157.

Duprez, D. M., Coltey, M., Amthor, H., Brickell, P. M., and Tickle, C. (1996). Bone  
Morphogenetic Protein-2 (BMP-2) inhibits muscle development and promotes  
20 cartilage formation in chick limb bud cultures. Developmental Biology 174, 448-452.

Eckhardt, K., and Schmitt, G. (1994). A retinoic receptor alpha antagonist counteracts  
retinoid teratogenicity in vitro and reduced incidence and/or severity of malformations  
in vivo. Toxicol. Lett. 70, 299-308

25 Ede, D. (1983). Cellular condensations and chondrogenesis. In Cartilage:  
Development, Differentiation and Growth, B. K. Hall, ed. (New York: Academic  
Press), pp. 143-185.

30 Eyrolles, L. et al. (1994). Retinoid Antagonists with a Heterocyclic Ring. J. Med.  
Chem. 37, 1508-1517.

- Ghyselinck, N. B., Dupe, V., Dierich, A., Messaddeq, N., Garnier, J. M., Rochettegly, C., Chambon, P., and Mark, M. (1997). Role of the Retinoic Acid Receptor Beta (RAR-Beta) During Mouse Development. *Int. J. Dev. Biol.* 41, 425-447.
- 5 Hall, B. K., and Miyake, T. (1995). Divide, accumulate, differentiate: cell condensation in skeletal development revisited. *Int. J. Dev. Biol.* 39, 881-893.
- Hall, B. K., and Miyake, T. (1992). The membranous skeleton: The role of cell  
10 condensations in vertebrate skeletogenesis. *Anat. Embryol.* 186, 107-124.
- Hogan, B. L. (1996). Bone morphogenetic proteins in development. *Current opinion in genetics and development* 6, 432-438.
- 15 Jones, C. M., Lyons, K. M., and Hogan, B. L. M. (1991). Involvement of Bone Morphogenetic Protein-4 (BMP-4) and Vgr-1 in morphogenesis and neurogenesis in the mouse. *Development* 111, 531-542.
- Kaneko, S. et al. (1991). Retinoid Antagonists. *Med. Chem. Res.* 1, 220-225.
- 20 Kastner, P., Messaddeq, N., Mark, M., Wendling, O., Grondona, J. M., Ward, S., Ghyselinck, N., and Chambon, P. (1997). Vitamin A deficiency and mutations of RXRalpha, RXRbeta and RARalpha lead to early differentiation of embryonic ventricular cardiomyocytes. *Development* 124, 4749-58.
- 25 Kingsley, D. M. (1994). The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. *Genes & Dev.* 8, 133-146.
- Kingsley, D. M., Bland, A. E., Grubber, J. M., Marker, P. C., Russell, L. B.,  
30 Copeland, N. G., and Jenkins, N. A. (1992). The mouse short ear skeletal morphogenesis locus is associated with defects in a bone morphogenetic member of the TGF-beta superfamily. *Cell* 71, 399-410.

Kistler, A. (1987). Limb bud cell cultures for estimating the teratogenic potential of compounds. *Arch. Toxicol.* 60, 403-414.

- 5 Kochhar, D. M. (1973). Limb development in mouse embryos. I. Analysis of teratogenic effects of retinoic acid. *Teratology* 7, 289-295.

Kochhar, D. M., and Aydelotte, M. B. (1974). Susceptible stages and abnormal morphogenesis in the developing mouse limb, analysed in organ culture after  
10 transplacental exposure to vitamin A (retinoic acid). *J. Embryol. Exp. Morph.* 31, 721-734.

- Kochhar, D. M., Jiang, H., Penner, J. D., Johnson, A. T., and Chandraratna, R. A. S. (1998). The use of a retinoid receptor antagonist in a new model to study vitamin a-  
15 dependent developmental events. *Int. J. Dev. Biol.* 42, 601-608.

Kwasigroch, T. E., and Kochhar, D. M. (1980). Production of congenital limb defects with retinoic acid: phenomenological evidence of progressive differentiation during limb morphogenesis. *Anat. Embryol.* 161, 105-113.  
20

Lee, K. H., Li, F. C. H., Yung, W. T., Kung, J. L. S., Ng, J. N., and Cheah, K. S. E. (1994). Influence of digits, ectoderm, and retinoic acid on chondrogenesis by mouse interdigital mesoderm in culture. *Dev. Dynam.* 201, 297-309.

- 25 Lohnes, D., Kastner, P., Dierich, A., Mark, M., LeMeur, M., and Chambon, P. (1993). Function of retinoic acid receptor gamma in the mouse. *Cell* 73, 643-658.

Lohnes, D., Mark, M., Mendelsohn, C., Dolle, P., Dierich, A., Gorry, P., Gansmuller, A., and Chambon, P. (1994). Function of the retinoic acid receptors (RARs) during  
30 development (I) Craniofacial and skeletal abnormalities in RAR double mutants. *Development* 120, 2723-2748.



- Lufkin, T., Lohnes, D., Mark, M., Dierich, A., Gorry, P., Gaub, M.-P., LeMeur, M., and Chambon, P. (1993). High postnatal lethality and testis degeneration in retinoic acid receptor alpha mutant mice. *Proc. Natl. Acad. Sci. USA* 90, 7225-7229.
- 5 Luo, G., Hofmann, C., Bronckers, A. L. J. J., Sohocki, M., Bradley, A., and Karsenty, G. (1995). BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. *Genes & Dev.* 9, 2808-2820.
- Luo, J., Pasceri, P., Conlon, R. A., Rossant, J., and Giguere, V. (1995). Mice lacking  
10 all isoforms of retinoic acid receptor beta develop normally and are susceptible to the teratogenic effects of retinoic acid. *Mech. Dev.* 53, 61-71.
- Lussier, M., Canoun, C., Ma, C., Sank, A., and Shuler, C. (1993). Interdigital soft tissue separation induced by retinoic acid in mouse limbs cultured in vitro. *Int. J. Dev.*  
15 *Biol.* 37, 555-564.
- Lyons, K. M., Pelton, R. W., and Hogan, B. L. M. (1990). Organogenesis and pattern formation in the mouse: RNA distribution patterns suggest a role for Bone Morphogenetic Protein-2A (BMP-2A). *Development* 109, 833-844.
- 20 Macias, D., Ganan, Y., Sampath, T. K., Piedra, M. E., Ros, M. a., and Hurle, J. M. (1997). Role of BMP-2 and OP-1 (BMP-7) in programmed cell death and skeletogenesis during chick limb development. *Development* 124, 1109-1117.
- 25 Mangelsdorf, D. J., Umesono, K., and Evans, R. M. (1994). The retinoid receptors. In *The Retinoids: Biology, Chemistry, and Medicine*, M. B. Sporn, A. B. Roberts and D. S. Goodman, eds. (New York: Raven Press Ltd.), pp. 319-349.
- Marigo, V., Johnson, R. L., Vortkamp, A., and Tabin, C. J. (1996). Sonic hedgehog  
30 differentially regulates expression of GLI and GLI3 during limb development. *Dev. Biol.* 180, 273-283.

- McBurney, M. W., Jones-Villeneuve, E. M. V., Edwards, M. K. S., and Anderson, P. J. (1982). Control of muscle and neuronal differentiation in cultured embryonal carcinoma cell line. *Nature* 299, 165-167.
- 5 Mendelsohn, C., Ruberte, E., LeMeur, M., Morriss-Kay, G., and Chambon, P. (1991). Developmental analysis of the retinoic acid-inducible RAR-beta2 promoter in transgenic animals. *Development* 113, 723-734.
- Minas, T., and Nehrer, S. (1997). Current concepts in the treatment of articular  
10 cartilage defects. *Orthopedics* 20, 525-538.
- Moses, H. L., and Serra, R. (1996). Regulation of differentiation by TGF-beta. *Current opinion in genetics and development* 6, 581-586.
- 15 Oberlender, S. A., and Tuan, R. S. (1994). Spatiotemporal profile of N-cadherin expression in the developing limb mesenchyme. *Cell Adhes Commun* 2, 521-37.
- Paulsen, D. F., Chen, W.-D., Okello, D., and Johnson, B. (1994a). Stage- and region-dependent responses of chick wing bud mesenchymal cells to retinoic acid in serum-  
20 free microcultures. *Dev. Dynam.* 201, 310-323.
- Paulsen, D. F., Solursh, M., Langille, R. M., Pang, L., and Chen, W.-D. (1994). Stable, position-related responses to retinoic acid by chick limb-bud mesenchymal cells in serum-free cultures. *In Vitro Cell. Dev. Biol.* 30A, 181-186.
- 25 Phillips, C. L., Morgan, A. L., Lever, L. W., and Wenstrup, R. J. (1992). Sequence analysis of a full-length cDNA for the murine Proa2(I) collagen chain: Comparison of the derived primary structure with human Proa2(I) collagen. *Genomics* 13, 1345-1346.

- Roark, E. F., and Greer, K. (1994). Transforming growth factor-b and bone morphogenetic protein-2 act by distinct mechanisms to promote chick limb cartilage differentiation in vitro. *Dev. Dynam.* 200, 103-116.
- 5 Rosen, V., Thies, R. S., and Lyons, K. (1996). Signaling pathways in skeletal formation: A role for BMP receptors. *Annals of the New York Academy of Science* 785, 59-69.
- Rosen, V., Wozney, J. M., Wang, E. A., Cordes, P., Celeste, A., McQuaid, D., and  
10 Kurtzberg, L. (1989). Purification and molecular cloning of a novel group of BMPs and localization of BMP mRNA in developing bone. *Connect Tissue Res* 20, 313-9.
- Ruberte, E., Dolle, P., Krust, A., Zelent, A., Morriss-Kay, G., and Chambon, P.  
15 (1990). Specific spatial and temporal distribution of retinoic acid receptor gamma transcripts during mouse embryogenesis. *Development* 108, 213-222.
- Shenefelt, R. E. (1972). Morphogenesis of malformations in hamsters caused by retinoic acid: relation to dose and stage at treatment. *Teratology* 5, 103-118.
- 20 Solloway, M. J., Dudley, A. T., Bikoff, E. K., Lyons, K. M., Hogan, B. L., and Robertson, E. J. (1998). Mice lacking Bmp6 function. *Dev Genet* 22, 321-39.
- Storm, E. E., Huynh, T. V., Copeland, N. G., Jenkins, N. A., Kingsley, D. M., and Lee, S.-J. (1994). Limb alterations in brachypodism mice due to mutations in a new  
25 member of the TGFb-superfamily. *Nature* 368, 639-643.
- Teng, M., Duong, T. T., Johnson, A. T., Klein, E. S., Wang, L., Khalifa, B., and Chandraratna, R. A. S. (1997). Identification of highly potent retinoic acid receptor alpha-selective antagonists. *J. Med. Chem.* 40, 2445-2451.

Underhill, T. M., Cash, D. E., and Linney, E. (1994). Constitutively active retinoid receptors exhibit interfamilial and intrafamilial promoter specificity. *Mol. Endo.* 8, 274-285.

- 5 Underhill, T. M., and Weston, A. D. (1998). Retinoids and their receptors in skeletal development. *Micro. Res. Tech.* 43, 137-155

Wang, E. A., Isreal, D. I., Kelly, S., and Luxenberg, D. P. (1993). Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and  
10 3T3 cells. *Growth factors* 9, 57-71.

Winnier, G., Blessing, M., Labosky, P. A., and Hogan, B. L. M. (1995). Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. *Genes & Dev.* 9, 2105-2116.

15 Wolpert, L. (1990). Signals in limb development: STOP, GO, STAY and POSITION. *J. Cell Sci. Suppl.* 13, 199-208.

Wozney, J. M., and Rosen, V. (1998). Bone morphogenetic protein and bone  
20 morphogenetic protein gene family in bone formation and repair. *Clin. Ortho. Rel. Res.* 346, 26-37.


Yokouchi, Y., Sakiyama, J., Kameda, T., Iba, H., Suzuki, A., Ueno, N., and Kuroiwa, A. (1996). BMP-2/-4 mediate programmed cell death in chicken limb buds.  
25 *Development* 122, 3725-3734.

Yoshimura, H. et al. (1995). A Novel Type of Retinoic Acid Receptor Antagonist: Synthesis and Structure-Activity Relationships of Heterocyclic Ring-Containing Benzoic Acid Derivatives. *J. Med. Chem.* 38, 3163-3173.

30 Zhang, H., and Bradley, A. (1996). Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. *Development* 122, 2977-2986.

- Zou, H., and Niswander, L. (1996). Requirement for BMP signalling in interdigital apoptosis and scale formation. *Science* 272, 738-741.
- 5 Zou, H., Wieser, R., Massague, J., and Niswander, L. (1997). Distinct roles of type I bone morphogenetic protein receptors in the formation and differentiation of cartilage. *Genes & Dev.* 11, 2191-2203.

	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---



AGN 194301

2-Fluoro-4-[(1-(8-bromo-2,2-dimethyl-4-(4-methylphenyl)-  
2-*H*-chromen-6-yl)-methanoyl)-amino]-benzoic acid

TABLE 1

## Claims:

1. A composition for inducing chondrogenesis and/or skeletal development in a  
5 vertebrate, the composition comprising:
  - (a) a RAR antagonist; and
  - (b) a pharmaceutically acceptable carrier.
2. The composition as claimed in claim 1, further comprising a protein selected  
10 from the group consisting of a bone morphogenic protein (BMP), an osteogenic protein (OPS) and a cytokine and combinations thereof.
3. The composition as claimed in claim 2, wherein said BMP is selected from the  
group consisting of BMP-2, BMP-4, and BMP-5.  
15
4. The composition as claimed in claim 3, wherein said osteogenic protein is OP-  
1.
5. The composition of claim 1, wherein the RAR antagonist is present in an  
20 amount capable of stimulating chondrogenesis and associated differentiation of skeletal progenitor cells.
6. The composition of claim 1, wherein said composition is provided as a  
solution, suspension, gel, matrix, film, paste, pill, tablet or encapsulated within  
25 liposomes.
7. The composition of claim 1, wherein said composition is administered via  
intra-articular injection.
- 30 8. The composition of claim 1, wherein said composition is provided within a biodegradable implantable matrix.

9. The use of a composition comprising an RAR antagonist and a pharmaceutically acceptable carrier, for inducing chondrogenesis.
10. The use of a composition of claim 9 wherein said use is *in vitro*.
- 5 11. The use of a composition of claim 9 wherein said use is *in vivo*.
12. A morphogenic device for implantation in a vertebrate, the device comprising:
- (a) an implantable biocompatible carrier; and
- 10 (b) an RAR antagonist dispersed within or on said carrier.
13. The device according to claim 12, wherein said carrier comprises demineralized, protein-extracted, particulate, allogenic or xenogenic bone.
- 15 14. The device according to claim 12, wherein said device comprises mineral-free, delipidated Type I insoluble collagen.
15. The device according to claim 12, wherein said device comprises a biodegradable sponge.
- 20 16. A method for producing a chondrocyte from a chondroprogenitor mesenchymal cell comprising contacting said chondroprogenitor mesenchymal cell with an RAR antagonist agent *in vitro*.
- 25 17. A method for promoting *in vivo* integration of an implantable prosthetic device, into a target cartilage tissue of a vertebrate, the method comprising the steps of:
- (a) providing on a surface of the prosthetic device a composition comprising an RAR antagonist and a pharmaceutically acceptable carrier and
- 30 (b) implanting the device in a vertebrate, at a site where the target cartilage tissue and surface of the prosthetic device are maintained at least partially in contact



15-11-2000

56am

From-SIM MCBURNEY

4165851153

T-706

P.10/10

F-418

CA 009901106

45

for a time sufficient to permit enhanced tissue growth between the target cartilage tissue and the device.

18 The method according to claim 19, wherein said target tissue is bone.

5

19. A method of treating a cartilage associated degenerative condition in a vertebrate comprising the step of administering a pharmaceutical composition as claimed in claim 1.

10 20. A method for promoting chondrogenesis and associated bone tissue formation at a site of skeletal surgery in a vertebrate, the method comprising the steps of delivering an RAR antagonist composition at the site of skeletal surgery wherein such delivery promotes the formation of new bone tissue.

15 21. A method for repairing large segmental skeletal gaps and non-union fractures arising from trauma or surgery in vertebrates, the method comprising delivering a RAR antagonist composition at the site of the segmental skeletal gap or non-union fracture wherein such delivery promotes chondrogenesis which mediates the formation of new bone tissue.

20

22. A method for aiding the attachment of implantable prosthesis at cartilaginous sites and for maintaining the long term stability of the prostheses in vertebrates, the method comprising coating selected regions of an implantable prosthesis with a RAR antagonist composition and implanting the coated prosthesis into a cartilaginous site

25 wherein such implantation promotes the formation of new cartilage tissue.

23 A method of producing cartilage at a cartilage defect *in vivo*, said method comprising:

- implanting into the defect a population of chondrogenic cells which

30 have been cultured in the presence of a RAR antagonist

24. A method for treating degenerative joint disease characterized by cartilage degeneration, said method comprising:

- delivering a therapeutically effective amount of an RAR antagonist to the site of disease.

5

25. The method according to claim 24, wherein said RAR antagonist is delivered by intra-articular injection.

26. The method according to claim 24, wherein said disease is arthritis.

10

27. An implantable prosthetic device for repairing an orthopedic defect, injury or anomaly in a vertebrate, said device comprising:

(a) a prosthetic implant having a surface region implantable adjacent or within a target tissue;

15

(b) an RAR antagonist composition disposed on said surface region in an amount sufficient to promote enhanced chondrogenesis and associated bone tissue growth into the surface.

20

28. The use of a composition comprising an RAR antagonist for inhibiting RAR activity and stimulating chondroblast differentiation.

29. The use of an RAR antagonist for decreasing transcriptional activation of the RA receptor and stimulating chondroblast differentiation.




FIGURE 1




FIGURE 2A




FIGURE 2B

4/9





FIGURE 3A







FIGURE 4





FIGURES 5A - 5L

8/9




FIGURE 5M




FIGURE 6

**DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION**  
Attorney Docket No. 3477-92

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **COMPOSITION AND USE OF RAR ANTAGONISTS FOR PROMOTING CHONDROGENESIS**,

the specification of which

☐ is attached hereto

OR

☒ was filed on November 19, 1999 as United States Application No. 09/856,324 or PCT

International Application Number \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT International application having a filing date before that of the application on which priority is claimed.

2,254,429	CA	11/19/1998	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed

			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed

			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)

Application Number(s)	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application (37 C.F.R. § 1.63(d)).

Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned

Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned

Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following registered attorney(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Customer Number 20792

Send correspondence to:

Kenneth D. Sibley  
Myers Bigel Sibley & Sajovec  
Post Office Box 37428  
Raleigh, NC 27627

Direct telephone calls to:

Kenneth D. Sibley  
(919)854-1400

Facsimile:

(919) 854-1401

Full name of (first/sole) inventor:

<sup>1-00</sup>  
Tully Michael UNDERHILL

Inventor's

Signature: X



Date: X

Aug. / 01

Residence:

Canada

Citizenship: X

Canadian

Post Office Address:

The University of Western Ontario  
Division of Oral Biology, School of Dentistry  
London, Ontario, N6A 5C1, Canada *CAX*

Full name of second inventor:

<sup>1-00</sup>  
Andrea Dawn WESTON

Inventor's

Signature: X



Date: X

August 1, 2001

Residence:

Canada


Citizenship: X

CANADIAN

Post Office Address:

The University of Western Ontario  
The Faculty of Medicine & Dentistry  
Department of Physiology  
London, Ontario, N6A 5C1, Canada *CAX*

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ *Scanned copy is best available.* Drawing are very dark.